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Background: Vagus Nerve Stimulation (VNS) has shown promising results for heart failure therapy. Current practice for VNS involves surgical 
dissection of the cervical vagus nerve. Transvenous stimulation near the vagus nerve might be less traumatic.
Methods: We evaluated the acute feasibility and safety of cervical VNS from the internal jugular vein (IJV) in patients (N=30) indicated for 
electrophysiology (EP) study. A decapolar EP catheter was positioned at various cervical levels in the IJV from the femoral (n=26) and left subclavian 
veins (n=4). Successful VNS was confirmed with laryngeal vibration (LVib) (innervation via recurrent laryngeal nerve). VNS thresholds were tested at 
20Hz and 500μs, at various current amplitudes for 15-20 seconds. Side effects of skeletal muscle stimulation or pain were noted.
Results: LVib was produced in all patients. The average threshold for LVib (1.4 ± 1.0 mA) was significantly lower than for side effects (2.8 ± 2.0 
mA, p<0.0001). VNS at the level of the 3rd cervical vertebra (C3) produced LVib without side effects in the most subjects (n=13). Location C2 had 
the lowest average threshold for LVib (0.97 ± 0.4 mA). Thresholds were significantly higher at locations lower down the spine (p <0.0001) but the 
correlation was weak (r2=0.22). See Figure 1 below.
Conclusions: This data suggests that VNS, at amplitudes necessary for laryngeal vibration, is safe and well-tolerated by transvenous approach from 
the IJV, and may offer an alternative approach for heart failure therapy.
